Bourgeois Pierre, Veys Isabelle, Noterman Danielle, De Neubourg Filip, Chintinne Marie, Vankerckhove Sophie, Nogaret Jean-Marie
Nuclear Medicine Service, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.
Surgery Service, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.
Front Oncol. 2021 Mar 9;11:602906. doi: 10.3389/fonc.2021.602906. eCollection 2021.
Near-infrared fluorescence imaging (NIRFI) of breast cancer (BC) after the intravenous (IV) injection of free indocyanine green (fICG) has been reported to be feasible. However, some questions remained unclarified.
To evaluate the distribution of fICG in BC and the axillary lymph nodes (LNs) of women undergoing surgery with complete axillary LN dissection (CALND) and/or selective lymphadenectomy (SLN) of sentinel LNs (NCT no. 01993576 and NCT no. 02027818).
An intravenous injection of fICG (0.25 mg/kg) was administered to one series of 20 women undergoing treatment with mastectomy, the day before surgery in 5 (group 1) and immediately before surgery in 15 (group 2: tumor localization, 25; and pN+ CALND, 4) as well as to another series of 20 women undergoing treatment with tumorectomy (group 3). A dedicated NIR camera was used for fluorescence imaging of the 45 BC lesions and the LNs.
In group 1, two of the four BC lesions and one large pN+ LN exhibited fluorescence. In contrast, 24 of the 25 tumors in group 2 and all of the tumors in group 3 were fluorescent. The sentinel LNs were all fluorescent, as well as some of the LNs in all CALND specimens. Metastatic cells were found in the fluorescent LNs of the pN+ cases. Fluorescent BC lesions could be identified on the surface of the lumpectomy specimen in 14 of 19 cases.
When fICG is injected intravenously just before surgery, BC can be detected using NIRFI with high sensitivity, with metastatic axillary LNs also showing fluorescence. Such a technical approach seems promising in the management of BC and merits further investigation.
据报道,静脉注射游离吲哚菁绿(fICG)后对乳腺癌(BC)进行近红外荧光成像(NIRFI)是可行的。然而,一些问题仍未得到澄清。
评估fICG在接受腋窝淋巴结完全清扫术(CALND)和/或前哨淋巴结选择性淋巴结切除术(SLN)的手术女性的乳腺癌及腋窝淋巴结(LNs)中的分布情况(NCT编号:01993576和NCT编号:02027818)。
对一组20例行乳房切除术的女性静脉注射fICG(0.25mg/kg),其中5例在手术前一天注射(第1组),15例在手术前即刻注射(第2组:肿瘤定位,25例;pN+ CALND,4例),另一组20例行肿瘤切除术的女性(第3组)也进行静脉注射。使用专用的近红外相机对45个乳腺癌病灶和淋巴结进行荧光成像。
在第1组中,4个乳腺癌病灶中的2个以及1个大的pN+淋巴结呈现荧光。相比之下,第2组的25个肿瘤中有24个以及第3组的所有肿瘤均有荧光。所有前哨淋巴结均有荧光,所有CALND标本中的一些淋巴结也有荧光。在pN+病例的荧光淋巴结中发现了转移细胞。在19例中的14例中,荧光乳腺癌病灶可在肿块切除标本表面识别出来。
在手术前即刻静脉注射fICG时,使用NIRFI可高灵敏度地检测到乳腺癌,腋窝转移淋巴结也会显示荧光。这种技术方法在乳腺癌的治疗中似乎很有前景,值得进一步研究。